GOT2 and thyroid gland carcinoma: Conversely, GOT2 had markedly lower expression in CHOL (Cholangiocarcinoma), GBM (Glioblastoma), KIRC (Kidney renal clear cell carcinoma), LIHC (Liver hepatocellular carcinoma), PRAD (Prostate adenocarcinoma) and THCA (Thyroid carcinoma).